Inebilizumab-Cdon: uses, dosing, side effects & brands
Inebilizumab-Cdon is a medicine sold in the U.S. under one brand, for neuromyelitis optica. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Neuromyelitis Optica
- Available as
- Injectable
- Sold as
- Uplizna
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How inebilizumab-cdon is dosed
From the FDA label for Uplizna (application BLA761142). Other inebilizumab-cdon products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Hepatitis B virus, quantitative serum immunoglobulins, and tuberculosis screening is required before the first dose. ( 2.1 ) Prior to every infusion: Determine if there is an active infection ( 2.2 , 5.2 ) Premedicate with a corticosteroid, an antihistamine, and an antipyretic ( 2.2 , 5.1 ) UPLIZNA must be diluted in 250 mL of 0.9% Sodium Chloride Injection, USP prior to administration. ( 2.3 , 2.4 ) UPLIZNA is administered as an intravenous infusion titrated to completion, approximately 90 minutes. The recommended dose is: Initial dose: 300 mg intravenous infusion followed two weeks later by a second 300 mg intravenous infusion. Subsequent doses (starting 6 months from the first infusion): single 300 mg intravenous infusion every 6 months. ( 2.3 ) Monitor patients closely during the infusion and for at least one hour after completion of the infusion. ( 2.3 ) 2.1 Assessments Prior to First Dose of UPLIZNA Hepatitis B Virus Screening Prior to initiating UPLIZNA, perform Hepatitis B virus (HBV) screening. UPLIZNA is contraindicated in patients with active HBV confirmed by positive results for surface antigen [HBsAg] and anti-HBV tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment with UPLIZNA [see Contraindications (4) and Warnings and…
Inebilizumab-Cdon side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Infusion Reactions [see Warnings and Precautions (5.1) ] Infections [see Warnings and Precautions (5.2) ] Reduction in Immunoglobulins [see Warnings and Precautions (5.3) ] The most common adverse reactions (at least 10% of patients treated with UPLIZNA and greater than placebo) were NMOSD: urinary tract infection and arthralgia. ( 6.1 ) IgG4-RD: urinary tract infections and lymphopenia. ( 6.1 ) gMG: headache and infusion-related reactions. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Inc. at 1-800-77-AMGEN (1-800-772-6436) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions NMOSD The safety of UPLIZNA was evaluated in Study 1, in which 161 patients were exposed to UPLIZNA at the recommended dosage regimen during the randomized, controlled treatment period; during which 52 patients received placebo [see Dosage and Administration (2.1) and Clinical Studies (14) ] . Subsequently, 198 patients were exposed to UPLIZNA during an open-label treatment period.…
Who shouldn’t take inebilizumab-cdon
UPLIZNA is contraindicated in patients with: A history of a life-threatening infusion reaction to UPLIZNA [see Warnings and Precautions (5.1) ] Active hepatitis B infection [see Warnings and Precautions (5.2) ] Active or untreated latent tuberculosis [see Warnings and Precautions (5.2) ] Previous life-threatening reaction to infusion of UPLIZNA ( 4 ) Active hepatitis B infection ( 4 ) Active or untreated latent tuberculosis ( 4 )
Inebilizumab-Cdon drug interactions
7.1 Immunosuppressive or Immune-Modulating Therapies Concomitant usage of UPLIZNA with immunosuppressant drugs, including systemic corticosteroids, may increase the risk of infection. Consider the risk of additive immune system effects when co-administering immunosuppressive therapies with UPLIZNA.
Every inebilizumab-cdon product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Uplizna.
What people report to the FDA about inebilizumab-cdon
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 2 reports naming inebilizumab-cdon, and the FDA flagged 50% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- hypersensitivity1 reports
- neuromyelitis optica spectrum disorder1 reports
Read these as a signal, not a rate. A report does not mean inebilizumab-cdon caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is inebilizumab-cdon?
Uplizna (Inebilizumab-Cdon) is a medication used to treat Neuromyelitis Optica.
Can you take inebilizumab-cdon with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run inebilizumab-cdon against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does inebilizumab-cdon come in?
Across the brands we track, inebilizumab-cdon is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic inebilizumab-cdon?
We do not currently list a generic-labelled inebilizumab-cdon product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Inebilizumab-Cdon: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/inebilizumab-cdon
- MLA
- “Inebilizumab-Cdon: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/inebilizumab-cdon.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for inebilizumab-cdon on DailyMed (NIH) ↗.